Page last updated: 2024-12-05

1,2-diaminoanthraquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1,2-Diaminoanthraquinone is a versatile organic compound used in various applications, including the synthesis of dyes and pigments. It is a yellow solid with a molecular formula of C14H10N2O2. The compound is typically synthesized through the reduction of 1,2-dinitroanthraquinone using a reducing agent such as sodium sulfide or sodium hydrosulfite. 1,2-Diaminoanthraquinone is an important intermediate in the production of various anthraquinone dyes, which are known for their exceptional lightfastness and durability. Its unique chemical structure allows for the creation of dyes with a wide range of color shades. The compound is also a key building block for the synthesis of other valuable organic molecules, such as pharmaceuticals and polymers. Research on 1,2-diaminoanthraquinone focuses on exploring its potential in developing novel dyes, pigments, and materials with enhanced properties. Studies also delve into its environmental impact and the development of sustainable synthesis methods. The compound's versatility and potential applications make it a subject of ongoing scientific interest.'

Cross-References

ID SourceID
PubMed CID15652
CHEMBL ID89626
SCHEMBL ID487001
MeSH IDM0303037

Synonyms (49)

Synonym
BIDD:GT0412
1,2-diamino-anthraquinone
CHEMBL89626 ,
ai3-61387
brn 2125604
ccris 5602
9,10-anthracenedione, 1,2-diamino-
1,2-daa [russian]
nsc 39934
1,2-diamino-9,10-anthraquinone
anthraquinone, 1,2-diamino-
einecs 217-156-2
1,2-diamino-9,10-anthracenedione
UPCMLD0ENAT5883742:001
9, 1,2-diamino-
nsc-39934
1758-68-5
anthraquinone,2-diamino-
nsc39934
1,2-daa
wln: l c666 bv ivj dz ez
1,2-diaminoanthraquinone
1,2-diaminoanthracene-9,10-dione
diaminoanthraquinone
STK396666
AKOS000120256
4-14-00-00456 (beilstein handbook reference)
unii-h5p6yp29va
h5p6yp29va ,
BBL013159
BP-12713
FT-0606332
DTXSID5061950
1, 2-diaminoanthraquinone
SCHEMBL487001
1,2-diaminoanthra-9,10-quinone #
W-109705
mfcd00001219
1,2-diamino-10-anthracenedione
VS-03693
1,2-diamino-9,10-dihydroanthracene-9,10-dione
EN300-18126
Q27279676
A881551
A03-0001
9,10-anthracenedione,1,2-diamino-
CS-W014151
HY-W013435
bdbm50599586
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)2.28000.00002.37899.7700AID1888748
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)2.41000.00001.89149.5700AID1888749
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)508.00000.00071.600310.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)508.00000.00071.630610.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)508.00000.00061.525710.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)508.00000.00071.747210.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)508.00000.00071.741110.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)508.00000.00071.741110.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)508.00000.00071.741110.0000AID144609; AID144610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID731485Inhibition of TERT transcriptional activity in human H1299 cells assessed SEAP activity at 1 uM incubated for 24 hrs by SEAP assay2013European journal of medicinal chemistry, Feb, Volume: 60Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
AID1888748Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID1070861Inhibition of human tert transcriptional activity assessed as SEAP activity at 1 uM after 24 hrs by SEAP reporter assay2013European journal of medicinal chemistry, Nov, Volume: 69Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID1070863Cytotoxicity against human H1299 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay2013European journal of medicinal chemistry, Nov, Volume: 69Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID1888750Selectivity index, ratio IC50 for recombinant human MAO-B to IC50 for recombinant human MAO-A2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID731487Cytotoxicity against human H1299 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
AID144610Displacement of [3H]-SPD from N-methyl-D-aspartate glutamate receptor2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-D-aspartate receptor complex.
AID1070859Inhibition of human tert transcriptional activity assessed as SEAP activity at 100 uM after 24 hrs by SEAP reporter assay2013European journal of medicinal chemistry, Nov, Volume: 69Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID731489Inhibition of TERT activity in human H1299 cells homogenates incubated for 5 mins at 100 uM by TRAP assay2013European journal of medicinal chemistry, Feb, Volume: 60Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
AID1070862Cytotoxicity against human H1299 cells assessed as cell viability at 100 uM after 48 hrs by MTT assay2013European journal of medicinal chemistry, Nov, Volume: 69Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID731486Cytotoxicity against human H1299 cells assessed as cell viability at 100 uM after 48 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
AID1888749Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID144609Displacement of [3H]MK-801 from N-methyl-D-aspartate glutamate receptor2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-D-aspartate receptor complex.
AID1070864Cytotoxicity against human H1299 cells assessed as cell viability at 1 uM after 48 hrs by MTT assay2013European journal of medicinal chemistry, Nov, Volume: 69Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID731488Cytotoxicity against human H1299 cells assessed as cell viability at 1 uM after 48 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
AID1070860Inhibition of human tert transcriptional activity assessed as SEAP activity at 10 uM after 24 hrs by SEAP reporter assay2013European journal of medicinal chemistry, Nov, Volume: 69Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID731484Inhibition of TERT transcriptional activity in human H1299 cells assessed SEAP activity at 10 uM incubated for 24 hrs by SEAP assay2013European journal of medicinal chemistry, Feb, Volume: 60Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
AID731483Inhibition of TERT transcriptional activity in human H1299 cells assessed SEAP activity at 100 uM incubated for 24 hrs by SEAP assay2013European journal of medicinal chemistry, Feb, Volume: 60Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's6 (42.86)29.6817
2010's6 (42.86)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.85 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index25.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]